NRP1

Summary

NRP1 (neuropilin 1, HGNC:8004) is a protein-coding gene on chromosome 10p11.22, encoding Neuropilin-1 (O14786). Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system.

This gene encodes one of two neuropilins, which contain specific protein domains which allow them to participate in several different types of signaling pathways that control cell migration. Neuropilins contain a large N-terminal extracellular domain, made up of complement-binding, coagulation factor V/VIII, and meprin domains. These proteins also contains a short membrane-spanning domain and a small cytoplasmic domain. Neuropilins bind many ligands and various types of co-receptors; they affect cell survival, migration, and attraction. Some of the ligands and co-receptors bound by neuropilins are vascular endothelial growth factor (VEGF) and semaphorin family members. This protein has also been determined to act as a co-receptor for SARS-CoV-2 (which causes COVID-19) to infect host cells.

Source: NCBI Gene 8829 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Limited, ClinGen)
• GWAS associations: 19
• Clinical variants (ClinVar): 326 total
• Druggable target: yes
• MANE Select transcript: NM_003873

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8004
Approved symbol	NRP1
Name	neuropilin 1
Location	10p11.22
Locus type	gene with protein product
Status	Approved
Aliases	NRP, VEGF165R, CD304
Ensembl gene	ENSG00000099250
Ensembl biotype	protein_coding
OMIM	602069
Entrez	8829

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 30 protein_coding

ENST00000265371, ENST00000374816, ENST00000374821, ENST00000374822, ENST00000374823, ENST00000374867, ENST00000374875, ENST00000395995, ENST00000413802, ENST00000418675, ENST00000431894, ENST00000432372, ENST00000455749, ENST00000466932, ENST00000897563, ENST00000897564, ENST00000897565, ENST00000949861, ENST00000949862, ENST00000949863, ENST00000949864, ENST00000949865, ENST00000949866, ENST00000949867, ENST00000949868, ENST00000949869, ENST00000949870, ENST00000949871, ENST00000949872, ENST00000949873

RefSeq mRNA: 6 — MANE Select: NM_003873 NM_001024628, NM_001024629, NM_001244972, NM_001244973, NM_001330068, NM_003873

CCDS: CCDS31179, CCDS31180, CCDS7177, CCDS81448

Canonical transcript exons

ENST00000374867 — 17 exons

Exon	Start	End
ENSE00003692282	33330708	33330882
ENSE00003843830	33177493	33180365
ENSE00003846627	33334310	33334667
ENSE00003889264	33207572	33207716
ENSE00003889307	33185628	33185724
ENSE00003889874	33263646	33263873
ENSE00003889907	33256316	33256471
ENSE00003890459	33226134	33226289
ENSE00003890797	33186217	33186488
ENSE00003891573	33192281	33192418
ENSE00003891852	33202891	33202995
ENSE00003892288	33213386	33213717
ENSE00003892454	33254028	33254194
ENSE00003892644	33270675	33270856
ENSE00003895271	33182698	33182748
ENSE00003895454	33221719	33221863
ENSE00003896141	33197650	33197709

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 98.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 77.0172 / max 1881.7679, expressed in 1640 samples.

FANTOM5 promoters (15 alternative TSS)

Promoter ID	TPM avg	Samples expressed
109064	24.5275	1531
109061	18.3302	1511
109058	13.6480	1326
109060	4.7502	1173
109059	4.6143	1099
109063	2.6997	1088
109062	2.6773	1009
109069	1.6882	1090
109065	1.4150	762
109067	0.9138	606

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.56	gold quality
pericardium	UBERON:0002407	98.19	gold quality
calcaneal tendon	UBERON:0003701	97.27	gold quality
peritoneum	UBERON:0002358	96.96	gold quality
omental fat pad	UBERON:0010414	96.96	gold quality
synovial joint	UBERON:0002217	96.79	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.79	gold quality
adrenal tissue	UBERON:0018303	96.36	gold quality
heart right ventricle	UBERON:0002080	96.04	gold quality
colonic epithelium	UBERON:0000397	96.01	gold quality
gall bladder	UBERON:0002110	96.01	gold quality
cardiac ventricle	UBERON:0002082	95.97	gold quality
heart left ventricle	UBERON:0002084	95.94	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.94	gold quality
adipose tissue	UBERON:0001013	95.78	gold quality
smooth muscle tissue	UBERON:0001135	95.65	gold quality
metanephros cortex	UBERON:0010533	95.40	gold quality
connective tissue	UBERON:0002384	95.32	gold quality
superficial temporal artery	UBERON:0001614	95.29	gold quality
heart	UBERON:0000948	95.15	gold quality
apex of heart	UBERON:0002098	95.11	gold quality
placenta	UBERON:0001987	94.98	gold quality
cauda epididymis	UBERON:0004360	94.88	gold quality
vena cava	UBERON:0004087	94.81	gold quality
right lobe of thyroid gland	UBERON:0001119	94.71	gold quality
islet of Langerhans	UBERON:0000006	94.65	gold quality
right atrium auricular region	UBERON:0006631	94.53	gold quality
sural nerve	UBERON:0015488	94.52	gold quality
cardiac atrium	UBERON:0002081	94.50	gold quality
tendon	UBERON:0000043	94.42	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-GEOD-98556	yes	373.03
E-GEOD-130473	yes	313.07
E-MTAB-7008	yes	126.22
E-MTAB-6678	yes	38.75
E-GEOD-135922	yes	21.65
E-HCAD-9	yes	15.89
E-MTAB-8271	yes	15.17
E-CURD-112	yes	14.84
E-CURD-119	yes	13.49
E-GEOD-93593	yes	12.37
E-MTAB-5061	yes	10.85
E-MTAB-9067	yes	8.27
E-MTAB-9801	yes	7.81
E-GEOD-83139	yes	7.29
E-ENAD-27	yes	6.58

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PHACTR1	Activation

Upstream regulators (CollecTRI, top): AR, ATF4, DLL4, E2F1, EMX1, ESR1, ETS1, EYA1, HAND2, MAX, NFE2L2, NOTCH1, NR2F2, NR4A2, PAX3, PROX1, REST, SP1, SSRP1, TFAP2A

Literature-anchored findings (GeneRIF, showing 40)

• A potential mechanism involved in hemangioma formation is the alteration of the NRP1 signaling pathway in endothelial and/or pericytic cells. (PMID:11807987)
• A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. (PMID:11953749)
• Neuropilin-1 is another neuronal molecule in the “immunological synapse”. (PMID:11976715)
• results suggest that NRP-1 may be a multiple function protein in human breast and may be involved in the induction of local invasiveness of neoplasia and angiogenesis and have direct relevance to the progression of breast cancer (PMID:12216067)
• promoter regions of human and mouse NRP1 genes were cloned and sequenced; transfection demonstrated that two Sp1 elements are major contributors to constitutive and induced activity (PMID:12577308)
• human glioma cells express class 3 semaphorins and receptors for soluble and membrane-bound semaphorins, suggesting a possible role of the semaphorin/neuropilin system in the interactions of human malignant glioma with the nervous and immune systems. (PMID:12730958)
• neuropilin-1 is expressed in the prostatic stromal cells, not epithelial tumor cells, and this expression is significantly increased in the malignant phenotype (PMID:12883660)
• breast carcinoma cells support an autocrine pathway involving SEMA3A, plexin-A1, and neuropilin-1 that impedes their ability to chemotax. (PMID:14500350)
• independently promote cell signaling in endothelial cells and also demonstrate the importance of last three amino acids for its function (PMID:14514674)
• Np-1 and Np-2 contribute to autocrine-paracrine interactions in pancreatic cancer (PMID:14760080)
• NP-1 has a specific role in mediating neurotrophic actions of VEGF family members (PMID:15126502)
• NRP1 overexpression contributes to tumor progression and has clinical significance for glioma. (PMID:15160992)
• Effect of NRP-1 overexpression on angiogenesis and growth of human colon adenocarcinoma by immunohistochemistry and in situ hybridization. (PMID:15161648)
• Increased expression of NRP1 is associated with an aggressive angiogenic phenotype in melanoma. (PMID:15166498)
• correlation between neuropilin-1 and vascularity in human astrocytic tumors and a possible role for neuropilin-1 as a receptor for VEGF-induced angiogenesis (PMID:15233640)
• dual role as an enhancer of VEGF activity and a mediator of endothelial cell adhesiveness (PMID:15522955)
• NP-1 mRNA was highly expressed in vascular endothelium and in stromal cells, but in these cells, NP-1 expression did not change during the menstrual cycle. (PMID:15613413)
• role for Npn-1 in regulating endothelial barrier dysfunction in response to VEGF. (PMID:15920019)
• Neuropilin-1 overexpression in pancreatic cancer cell lines is associated with (a) increased constitutive MAPK signalling, (b) inhibition of anoikis, and (c) chemoresistance (PMID:15956974)
• Down-regulation of NRP1 by NRSF overexpression reduced Sema3A activity. It was concluded that NRSF is a transcription factor that silences NRP1 expression and thereby diminishes the Sema3A mediated inhibition of HaCaT keratinocyte migration (PMID:16330548)
• Data show that tuftsin and a higher affinity antagonist, TKPPR, bind selectively to neuropilin-1 and block vascular endothelial growth factor (VEGF) binding to that receptor. (PMID:16371354)
• Preferential receptor binding and internalization by a ligand are mechanisms by which the common receptor Npn-1 can play an essential role in prioritizing conflicting signals. (PMID:16424390)
• This study describes the first specific antagonist of VEGF-A165 binding to NP-1 and demonstrate that NP-1 is essential for optimum KDR activation and intracellular signaling. (PMID:16513643)
• Immunohistochemical staining showed that NRP-1 was mainly confined to stroma and blood vessels and only in late-proliferative endometrium, epithelial staining was also observed. (PMID:16648151)
• GAG modification of NRP1 plays a critical role in modulating VEGF signaling, and may provide new insights into physiological and pathological angiogenesis. (PMID:16763549)
• NRP1 is involved in HTLV-1 and HTLV-2 entry (PMID:16809290)
• depletion of neuropilin-1 production by aortic smooth muscle cells with specific short hairpin RNA prevents the PDGF-dependent migration of vascular smooth muscle cells (PMID:16847823)
• NRP1 transfer to T lymphocytes during the immune synapse can convert T lymphocytes into vascular endothelial growth factor (VEGF)165-carrying cells. (PMID:16849452)
• increased NRP-1 expression in acute myeloid leukemia with significant correlation to survival (PMID:16990775)
• down-regulation of the neuropilin-1 transcripts by short interfering RNA caused spontaneous synoviocyte apoptosis, which was associated with both the decrease in Bcl-2 expression and the increase in Bax translocation to mitochondria. (PMID:17015762)
• Neuropilin-1 was expressed in most of human laryngeal carcinoma specimens and cell lines but was not expressed in nonmalignant tissue. (PMID:17017185)
• These results suggest that the expression of VEGFRs and NRPs on keratinocytes may constitute important regulators for its activity and may possibly be responsible for the autocrine signaling in the epidermis. (PMID:17088944)
• NP-1/Sema-3A-mediated interactions participate in the control of human thymocyte development (PMID:17369353)
• Data suggest that tumor cell-expressed NRP1 promotes glioma progression through potentiating the activity of the HGF/SF autocrine c-Met signaling pathway and enhancing angiogenesis. (PMID:17369861)
• NRP-1 expression was augmented threefold during malignant transformation of ovarian epithelial cells with oncogene ras, suggesting an association between NRP-1 and oncogenesis. (PMID:17376520)
• VEGF(121) binds directly to NRP1; however, unlike VEGF(165), VEGF(121) is not sufficient to bridge the NRP1.VEGFR2 complex. (PMID:17575273)
• Np-1 confers a growth and survival advantage to pancreas cancer cells, and interacts with integrin beta1 to coordinate signaling events that promote cell adherence and invasiveness. (PMID:17726369)
• neoplastic cells in myeloid leukemias frequently express VEGFR including NRP-1 and NRP-2 (PMID:17917967)
• These findings indicate that Np-1 is required for efficient activation of c-Met-dependent pathways that promote cell invasiveness. (PMID:17974973)
• This study, by elucidating the mechanisms that govern VPF/VEGF-induced EC survival signaling via NRP-1, contributes to a better understanding of molecular mechanisms of cardiovascular development (PMID:18000534)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	nrp1a	ENSDARG00000102153
mus_musculus	Nrp1	ENSMUSG00000025810
rattus_norvegicus	Nrp1	ENSRNOG00000010744

Paralogs (35): NRXN3 (ENSG00000021645), TLL1 (ENSG00000038295), CP (ENSG00000047457), DCBLD2 (ENSG00000057019), HEPH (ENSG00000089472), TLL2 (ENSG00000095587), PCOLCE (ENSG00000106333), CNTNAP3 (ENSG00000106714), CUBN (ENSG00000107611), CNTNAP1 (ENSG00000108797), NRXN2 (ENSG00000110076), MEP1A (ENSG00000112818), NRP2 (ENSG00000118257), CUZD1 (ENSG00000138161), MFGE8 (ENSG00000140545), MEP1B (ENSG00000141434), PDGFC (ENSG00000145431), CNTNAP4 (ENSG00000152910), CNTNAP3B (ENSG00000154529), CNTNAP5 (ENSG00000155052), CDCP2 (ENSG00000157211), PCOLCE2 (ENSG00000163710), EDIL3 (ENSG00000164176), NETO1 (ENSG00000166342), BMP1 (ENSG00000168487), PDGFD (ENSG00000170962), NETO2 (ENSG00000171208), CNTNAP2 (ENSG00000174469), NRXN1 (ENSG00000179915), HEPHL1 (ENSG00000181333), F8 (ENSG00000185010), ASTL (ENSG00000188886), F5 (ENSG00000198734), MFRP (ENSG00000235718), CNTNAP3C (ENSG00000283378)

Protein

Protein identifiers

Neuropilin-1 — O14786 (reviewed: O14786)

Alternative names: Vascular endothelial cell growth factor 165 receptor

All UniProt accessions (11): O14786, E7EX60, E9PEP6, H0Y4A0, H0Y4N6, H0Y7Z2, Q5JWQ2, Q5JWQ4, Q5JWQ6, Q5T7F0, V9GYL7

UniProt curated annotations — full annotation on UniProt →

Function. Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. Mediates the chemorepulsant activity of semaphorins. Recognizes a C-end rule (CendR) motif R/KXXR/K on its ligands which causes cellular internalization and vascular leakage. It binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF165 isoform of VEGFA and VEGFB. Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulates VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Regulates mitochondrial iron transport via interaction with ABCB8/MITOSUR. (Microbial infection) Acts as a host factor for human coronavirus SARS-CoV-2 infection. Recognizes and binds to CendR motif RRAR on SARS-CoV-2 spike protein S1 which enhances SARS-CoV-2 infection. Binds VEGF-165 and may inhibit its binding to cells. May induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity.

Subunit / interactions. Homodimer, and heterodimer with NRP2. Interacts with FER. Interacts with PLXNB1. Interacts with VEGFA. Interacts with ABCB8/MITOSUR in mitochondria. (Microbial infection) Interacts with SARS coronavirus-2/SARS-CoV-2 spike protein S1 (via the CendR motif RRAR).

Subcellular location. Secreted Mitochondrion membrane. Cell membrane. Cytoplasm.

Tissue specificity. The expression of isoforms 1 and 2 does not seem to overlap. Expressed in olfactory epithelium (at protein level). Expressed in fibroblasts (at protein level). Expressed by the blood vessels of different tissues. In the developing embryo it is found predominantly in the nervous system. In adult tissues, it is highly expressed in heart and placenta; moderately in lung, liver, skeletal muscle, kidney and pancreas; and low in adult brain. Expressed in the central nervous system, including olfactory related regions such as the olfactory tubercles and paraolfactory gyri. The expression of isoforms 1 and 2 does not seem to overlap. Found in liver hepatocytes, kidney distal and proximal tubules.

Domain organisation. The tandem CUB domains mediate binding to semaphorin, while the tandem F5/8 domains are responsible for heparin and VEGF binding. F5/8 domains mediate the recognition and binding to R/KXXR/K CendR motifs.

Similarity. Belongs to the neuropilin family.

Isoforms (3)

UniProt ID	Names	Canonical?
O14786-1	1, Membrane-bound	yes
O14786-2	2, Soluble, SNRP1
O14786-3	3

RefSeq proteins (6): NP_001019799, NP_001019800, NP_001231901, NP_001231902, NP_001316997, NP_003864* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000421	FA58C	Domain
IPR000859	CUB_dom	Domain
IPR000998	MAM_dom	Domain
IPR008979	Galactose-bd-like_sf	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR014648	Neuropilin	Family
IPR022579	Neuropilin_C	Domain
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily
IPR050633	Neuropilin_MCO_CoagFactor	Family

Pfam: PF00431, PF00629, PF00754, PF11980

UniProt features (101 total): strand 41, turn 12, helix 9, glycosylation site 8, disulfide bond 6, domain 5, sequence conflict 4, binding site 3, splice variant 3, sequence variant 3, topological domain 2, signal peptide 1, chain 1, region of interest 1, modified residue 1, transmembrane region 1

Structure

Experimental structures (PDB)

25 structures.

PDB	Method	Resolution (Å)
6FMC	X-RAY DIFFRACTION	0.9
6TKK	X-RAY DIFFRACTION	1.06
8PFE	X-RAY DIFFRACTION	1.35
5JGI	X-RAY DIFFRACTION	1.38
5C7G	X-RAY DIFFRACTION	1.45
5IJR	X-RAY DIFFRACTION	1.52
9EOU	X-RAY DIFFRACTION	1.55
7O1N	X-RAY DIFFRACTION	1.56
9F6B	X-RAY DIFFRACTION	1.57
5IYY	X-RAY DIFFRACTION	1.6
5JGQ	X-RAY DIFFRACTION	1.6
7P5U	X-RAY DIFFRACTION	1.6
4RN5	X-RAY DIFFRACTION	1.73
2QQI	X-RAY DIFFRACTION	1.8
5JHK	X-RAY DIFFRACTION	1.8
1KEX	X-RAY DIFFRACTION	1.9
2QQM	X-RAY DIFFRACTION	2
5J1X	X-RAY DIFFRACTION	2.1
2QQN	X-RAY DIFFRACTION	2.2
5L73	X-RAY DIFFRACTION	2.24
7JJC	X-RAY DIFFRACTION	2.36
4DEQ	X-RAY DIFFRACTION	2.65
8C5G	X-RAY DIFFRACTION	2.7
6FMF	X-RAY DIFFRACTION	2.81
3I97	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14786-F1	79.83	0.47

Antibody-complex structures (SAbDab): 1 — 2QQN

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 195; 209; 250

Post-translational modifications (1): 894

Disulfide bonds (6): 27–54, 82–104, 147–173, 206–228, 275–424, 431–583

Glycosylation sites (8): 150, 261, 300, 522, 612, 612, 829, 842

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-194306	Neuropilin interactions with VEGF and VEGFR
R-HSA-376176	Signaling by ROBO receptors
R-HSA-399954	Sema3A PAK dependent Axon repulsion
R-HSA-399955	SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
R-HSA-399956	CRMPs in Sema3A signaling
R-HSA-445144	Signal transduction by L1
R-HSA-447041	CHL1 interactions
R-HSA-9694614	Attachment and Entry

MSigDB gene sets: 938 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_PLATELET_DERIVED_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_FOREBRAIN_NEURON_DEVELOPMENT, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_DENDRITE_DEVELOPMENT, MODULE_92, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, AAGCAAT_MIR137, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_NEURON_RECOGNITION, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, GOBP_CARDIAC_SEPTUM_DEVELOPMENT

GO Biological Process (92): angiogenesis (GO:0001525), branching involved in blood vessel morphogenesis (GO:0001569), vasculogenesis (GO:0001570), neural crest cell migration (GO:0001755), neuron migration (GO:0001764), positive regulation of endothelial cell proliferation (GO:0001938), sprouting angiogenesis (GO:0002040), cell migration involved in sprouting angiogenesis (GO:0002042), outflow tract septum morphogenesis (GO:0003148), substrate-dependent cell migration, cell extension (GO:0006930), signal transduction (GO:0007165), integrin-mediated signaling pathway (GO:0007229), cell-cell signaling (GO:0007267), axon guidance (GO:0007411), axonal fasciculation (GO:0007413), motor neuron axon guidance (GO:0008045), response to wounding (GO:0009611), animal organ morphogenesis (GO:0009887), positive regulation of endothelial cell migration (GO:0010595), positive regulation of smooth muscle cell migration (GO:0014911), facial nerve structural organization (GO:0021612), trigeminal nerve structural organization (GO:0021637), vestibulocochlear nerve structural organization (GO:0021649), branchiomotor neuron axon guidance (GO:0021785), gonadotrophin-releasing hormone neuronal migration to the hypothalamus (GO:0021828), regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030947), retinal ganglion cell axon guidance (GO:0031290), regulation of Cdc42 protein signal transduction (GO:0032489), cellular response to hepatocyte growth factor stimulus (GO:0035729), endothelial cell chemotaxis (GO:0035767), cellular response to vascular endothelial growth factor stimulus (GO:0035924), ventral trunk neural crest cell migration (GO:0036486), neuropilin signaling pathway (GO:0038189), VEGF-activated neuropilin signaling pathway (GO:0038190), positive regulation of phosphorylation (GO:0042327), negative regulation of neuron apoptotic process (GO:0043524), positive regulation of angiogenesis (GO:0045766), symbiont entry into host cell (GO:0046718), platelet-derived growth factor receptor signaling pathway (GO:0048008), vascular endothelial growth factor receptor signaling pathway (GO:0048010)

GO Molecular Function (11): vascular endothelial growth factor receptor activity (GO:0005021), GTPase activator activity (GO:0005096), heparin binding (GO:0008201), coreceptor activity (GO:0015026), semaphorin receptor activity (GO:0017154), growth factor binding (GO:0019838), protein kinase binding (GO:0019901), cytokine binding (GO:0019955), vascular endothelial growth factor binding (GO:0038085), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (19): semaphorin receptor complex (GO:0002116), obsolete extracellular space (GO:0005615), early endosome (GO:0005769), cytosol (GO:0005829), neurofilament (GO:0005883), plasma membrane (GO:0005886), focal adhesion (GO:0005925), axon (GO:0030424), cytoplasmic vesicle (GO:0031410), mitochondrial membrane (GO:0031966), neuron projection (GO:0043005), signaling receptor complex (GO:0043235), postsynaptic membrane (GO:0045211), sorting endosome (GO:0097443), glutamatergic synapse (GO:0098978), extracellular region (GO:0005576), cytoplasm (GO:0005737), mitochondrion (GO:0005739), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Semaphorin interactions	3
L1CAM interactions	2
Signaling by VEGF	1
Axon guidance	1
Early SARS-CoV-2 Infection Events	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
cellular anatomical structure	4
blood vessel morphogenesis	3
angiogenesis	2
cell communication	2
signaling	2
positive regulation of cell migration	2
protein binding	2
endosome	2
anatomical structure formation involved in morphogenesis	1
branching morphogenesis of an epithelial tube	1
cell differentiation	1
neural crest cell development	1
mesenchymal cell migration	1
cell migration	1
generation of neurons	1
endothelial cell proliferation	1
regulation of endothelial cell proliferation	1
positive regulation of epithelial cell proliferation	1
sprouting angiogenesis	1
blood vessel endothelial cell migration	1
outflow tract morphogenesis	1
cardiac septum morphogenesis	1
substrate-dependent cell migration	1
plasma membrane bounded cell projection assembly	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
cell surface receptor signaling pathway	1
axonogenesis	1
neuron projection guidance	1
neuron recognition	1
axon development	1
neuron projection fasciculation	1
axon guidance	1
response to stress	1
anatomical structure morphogenesis	1
animal organ development	1
regulation of endothelial cell migration	1
endothelial cell migration	1

Protein interactions and networks

STRING

2336 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRP1	SEMA3A	Q14563	999
NRP1	PLXNA1	Q9UIW2	998
NRP1	KDR	P35968	997
NRP1	PGF	P49763	997
NRP1	PLXNA4	Q9HCM2	997
NRP1	VEGFB	P49765	996
NRP1	PLXNA3	P51805	996
NRP1	SEMA3F	Q13275	994
NRP1	PLXNA2	O75051	992
NRP1	SEMA3B	Q13214	992
NRP1	GIPC1	O14908	990
NRP1	FLT1	P16057	990
NRP1	SEMA3D	O95025	986
NRP1	L1CAM	P32004	985
NRP1	SEMA3C	Q99985	979

IntAct

109 interactions, top by confidence:

A	B	Type	Score
ARRDC1	WWP2	psi-mi:“MI:0914”(association)	0.850
NRP1	CSNK2A2	psi-mi:“MI:0914”(association)	0.790
NRP1	VEGFA	psi-mi:“MI:0915”(physical association)	0.770
VEGFA	NRP1	psi-mi:“MI:0915”(physical association)	0.770
KDR	NRP1	psi-mi:“MI:0915”(physical association)	0.700
S	NRP1	psi-mi:“MI:0914”(association)	0.640
NRP1	S	psi-mi:“MI:0407”(direct interaction)	0.640
NRP1	S	psi-mi:“MI:0915”(physical association)	0.640
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
FLNA	NRP1	psi-mi:“MI:0407”(direct interaction)	0.560
NRP1	FLNA	psi-mi:“MI:0407”(direct interaction)	0.560
EVA1C	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
GPR183	NRP1	psi-mi:“MI:0914”(association)	0.530
TAFA4	NRP1	psi-mi:“MI:0914”(association)	0.530
TMX1	NRP1	psi-mi:“MI:0914”(association)	0.530
FZD10	NRP1	psi-mi:“MI:0914”(association)	0.530
LIPG	NRP1	psi-mi:“MI:0914”(association)	0.530

BioGRID (425): NRP1 (Affinity Capture-MS), PDGFB (Affinity Capture-Western), KDR (Affinity Capture-Western), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), NRP1 (Affinity Capture-Western), NRP1 (Affinity Capture-MS), KCTD9 (Affinity Capture-MS), BCS1L (Affinity Capture-MS)

ESM2 similar proteins: A2AJ76, F1QVU0, O08628, O14786, O88204, O89103, P09529, P0DV84, P15306, P28824, P42917, P79795, P97333, P97793, P97857, Q14393, Q15113, Q501P1, Q53RD9, Q5RBP1, Q60750, Q61398, Q61592, Q61810, Q63772, Q6UXI9, Q80ZD7, Q80ZD8, Q8K099, Q8N441, Q8N8Z6, Q8NDA2, Q8WXS8, Q91V88, Q923P0, Q96NU0, Q9BXP8, Q9BZ76, Q9ESS6, Q9ET61

Diamond homologs: A2AJA7, O14786, P28824, P85171, P98072, P98073, P98157, Q0PMG2, Q0WYX8, Q63191, Q6UXC1, Q8NFP4, Q8QFX6, Q9QWJ9, A2RUV9, A5A6K7, O17754, O18806, O35276, O35375, O35474, O43854, O54858, O54991, O60462, O75976, O88783, O89001, P00451, P02886, P02887, P02888, P04836, P12259, P12263, P14384, P15087, P15169, P16870, P21956

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
DLL4	“down-regulates quantity by repression”	NRP1	“transcriptional regulation”
NRP1	“up-regulates quantity by expression”	PHACTR1	“transcriptional regulation”
NRP1	“form complex”	“CoV2 spike protein-NRP1”	binding
SEMA3B	“up-regulates activity”	NRP1	binding
SEMA3A	“up-regulates activity”	NRP1	binding
SEMA3A	down-regulates	NRP1	binding
EMX1	“up-regulates quantity by expression”	NRP1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

326 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	184
Likely benign	102
Benign	16

Top pathogenic / likely-pathogenic (0)

SpliceAI

3137 predictions. Top by Δscore:

Variant	Effect	Δscore
10:33180362:CTCC:C	acceptor_gain	1.0000
10:33180363:TCC:T	acceptor_gain	1.0000
10:33180364:CC:C	acceptor_gain	1.0000
10:33180364:CCCTA:C	acceptor_gain	1.0000
10:33180365:CCTA:C	acceptor_gain	1.0000
10:33180366:C:A	acceptor_loss	1.0000
10:33180366:C:CC	acceptor_gain	1.0000
10:33180368:A:C	acceptor_gain	1.0000
10:33182758:C:CT	acceptor_gain	1.0000
10:33182767:T:TC	acceptor_gain	1.0000
10:33185622:ACTT:A	donor_loss	1.0000
10:33185623:CT:C	donor_loss	1.0000
10:33185624:TT:T	donor_loss	1.0000
10:33185625:TA:T	donor_loss	1.0000
10:33185626:A:AC	donor_gain	1.0000
10:33185626:ACT:A	donor_loss	1.0000
10:33185627:C:CC	donor_gain	1.0000
10:33185627:C:CG	donor_loss	1.0000
10:33192435:G:GC	acceptor_gain	1.0000
10:33207567:ATTAC:A	donor_loss	1.0000
10:33207568:TTA:T	donor_loss	1.0000
10:33207569:TA:T	donor_loss	1.0000
10:33207717:C:CC	acceptor_gain	1.0000
10:33221864:C:CC	acceptor_gain	1.0000
10:33226128:A:C	donor_gain	1.0000
10:33226128:ACTT:A	donor_loss	1.0000
10:33226129:CTTA:C	donor_loss	1.0000
10:33226130:TTACA:T	donor_loss	1.0000
10:33226131:T:TG	donor_loss	1.0000
10:33226132:A:AC	donor_gain	1.0000

AlphaMissense

6118 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:33180253:A:C	S865R	1.000
10:33180253:A:T	S865R	1.000
10:33180255:T:G	S865R	1.000
10:33192324:C:A	W673C	1.000
10:33192324:C:G	W673C	1.000
10:33192326:A:G	W673R	1.000
10:33192326:A:T	W673R	1.000
10:33254066:A:G	W315R	1.000
10:33254066:A:T	W315R	1.000
10:33270704:A:G	F134S	1.000
10:33270731:G:A	S125F	1.000
10:33330788:C:A	W56C	1.000
10:33330788:C:G	W56C	1.000
10:33330790:A:G	W56R	1.000
10:33330790:A:T	W56R	1.000
10:33180234:C:G	G872R	0.999
10:33180234:C:T	G872R	0.999
10:33180246:C:G	G868R	0.999
10:33180246:C:T	G868R	0.999
10:33186262:C:A	W763C	0.999
10:33186262:C:G	W763C	0.999
10:33186421:G:C	S710R	0.999
10:33186421:G:T	S710R	0.999
10:33186423:T:G	S710R	0.999
10:33192354:C:A	W663C	0.999
10:33192354:C:G	W663C	0.999
10:33207707:C:G	G542R	0.999
10:33221787:C:G	R405P	0.999
10:33226182:G:C	S363R	0.999
10:33226182:G:T	S363R	0.999

dbSNP variants (sampled 300 via entrez): RS1000002801 (10:33293342 G>A,T), RS1000016611 (10:33266124 C>T), RS1000025753 (10:33270918 A>C,G), RS1000049792 (10:33322709 A>G), RS1000064905 (10:33266422 G>A), RS1000069820 (10:33227192 T>G), RS1000091315 (10:33200247 G>T), RS1000129222 (10:33260253 T>C), RS1000180194 (10:33179368 T>C), RS1000204366 (10:33177826 C>T), RS1000213983 (10:33280757 A>T), RS1000229961 (10:33260626 G>A), RS1000240008 (10:33304925 A>C), RS1000248330 (10:33319290 G>A), RS1000254019 (10:33298925 C>T)

Disease associations

OMIM: gene MIM:602069 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Limited	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Limited	AR

Mondo (1): congenital heart disease (MONDO:0005453)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST001119_1	Schizophrenia	6.000000e-06
GCST001807_2	Tetralogy of Fallot	2.000000e-07
GCST003720_37	Migraine	2.000000e-09
GCST004746_21	Small cell lung carcinoma	1.000000e-06
GCST005196_29	Coronary artery disease	3.000000e-06
GCST006585_233	Blood protein levels	1.000000e-14
GCST006585_917	Blood protein levels	3.000000e-25
GCST010241_88	Apolipoprotein A1 levels	5.000000e-13
GCST010242_234	HDL cholesterol levels	1.000000e-08
GCST010242_37	HDL cholesterol levels	2.000000e-15
GCST010396_57	Gut microbiota (bacterial taxa, hurdle binary method)	8.000000e-06
GCST010703_186	Brain morphology (MOSTest)	6.000000e-11
GCST90002405_257	Reticulocyte count	3.000000e-09
GCST90013445_49	Type 1 diabetes	3.000000e-15
GCST90013445_59	Type 1 diabetes	3.000000e-15
GCST90020025_387	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020025_388	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020027_867	Waist-hip index	2.000000e-08
GCST90020027_868	Waist-hip index	3.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007874	gut microbiome measurement
EFO:0004346	neuroimaging measurement
EFO:0007986	reticulocyte count
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL5174 (SINGLE PROTEIN), CHEMBL5482974 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2070296	Efficacy	3	ranibizumab	Macular Degeneration

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2070296	NRP1	3	2.25	1	ranibizumab
rs2229935	NRP1		0.00	0
rs2247383	NRP1		0.00	0
rs2804495	NRP1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Neuropilins and Plexins

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
EG01377	Competitive	5.88	pKd
EG00229	Competitive	5.05	pIC50

Binding affinities (BindingDB)

34 measured of 480 human assays (496 total across all organisms); most potent 34 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
2-methoxy-N-(2-morpholinophenyl)-5-(phthalimidomethyl)benzamide	EC50	340 nM
cid_2467179	EC50	577 nM
4-[(2S)-4-methyl-1-phenoxypentan-2-yl]-1-(2-phenylethyl)-1,4-diazepan-5-one	EC50	2690 nM
1,1-bis(oxidanylidene)-2-(phenylmethyl)-3,4-dihydro-1,2-benzothiazepin-5-one	EC50	3060 nM
4-[(N-besylanilino)methyl]-N-(2,6-diethylphenyl)benzamide	EC50	3430 nM
N-(4-hydroxyphenyl)-2-(4-isobutylphenyl)propanamide	EC50	3770 nM
4-[(4-methyl-5,6,7,8-tetrahydroquinazolin-2-yl)sulfanylmethyl]benzoic acid	IC50	4530 nM
cid_2535143	IC50	7370 nM
3-(2-pyridinylamino)-2H-isoquinolin-1-one	IC50	7380 nM
SMR000120104	IC50	9900 nM
cid_3251511	IC50	10600 nM
5-azanyl-3-(4-chlorophenyl)-N-[(E)-(4-methoxyphenyl)methylideneamino]-4-oxidanylidene-thieno[3,4-d]pyridazine-1-carboxamide	IC50	11900 nM
(1-phenylpyrazolo[3,4-d]pyrimidin-4-yl)diazane	EC50	12800 nM
SMR000061158	IC50	18900 nM
SMR000335434	IC50	19900 nM
cid_16193520	IC50	20100 nM
2-[6-hydroxy-5-methyl-1-(4-methylphenyl)-4-oxopyrimidin-2-yl]sulfanyl-N-(3-methoxyphenyl)acetamide	IC50	20100 nM
cid_665545	IC50	23200 nM
MLS000046765	IC50	27700 nM
1-[4-(1-azanyl-2-methyl-propyl)-1,3-thiazol-2-yl]-3-[3-(trifluoromethyl)phenyl]urea	IC50	29900 nM
(4E)-5-methyl-4-[(3-nitroanilino)methylene]-2-phenyl-2-pyrazoline-3-thione	IC50	31100 nM
quinolin-8-yl N-[(2,4-dichlorophenyl)amino]-2-oxidanylidene-propanimidothioate	IC50	32200 nM
2-(2-methylphenoxy)-N-[(2-methylphenyl)carbamothioyl]ethanamide	IC50	33800 nM
[4-(4-Chloro-phenyl)-5-(2,4-dichloro-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-acetic acid	IC50	34400 nM
(6Z)-6-(3-pyrazolin-3-ylidene)cyclohexa-2,4-dien-1-one	IC50	35000 nM
4-methyl-N’-(4-methylphenyl)benzenesulfonohydrazide	IC50	37900 nM
SMR000127729	IC50	38000 nM
ethyl 2-(1,3-benzodioxol-5-ylamino)ethanoate	IC50	38700 nM
cid_4557552	IC50	39500 nM
cid_4875488	IC50	40100 nM
MLS000516671	IC50	40500 nM
MLS000554687	IC50	56100 nM
3-chloranyl-5-(3,4-dimethoxyphenyl)-7-(trifluoromethyl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid	IC50	57500 nM
MLS000031979	IC50	75600 nM

ChEMBL bioactivities

119 potent at pChembl≥5 of 191 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.22	IC50	0.598	nM	CHEMBL5557974
7.87	Kd	13.4	nM	CHEMBL5591272
7.75	Kd	17.6	nM	CHEMBL5594653
7.65	Kd	22.5	nM	CHEMBL5575279
7.41	IC50	39	nM	CHEMBL5398256
7.37	IC50	43.05	nM	CHEMBL5398256
7.34	IC50	46	nM	CHEMBL5421065
7.33	IC50	46.24	nM	CHEMBL5421065
7.12	Kd	76	nM	CHEMBL4207210
7.12	Kd	76.3	nM	CHEMBL5570585
7.01	Kd	96.7	nM	CHEMBL5572893
6.98	Kd	105.6	nM	CHEMBL5574160
6.48	IC50	330	nM	CHEMBL5424756
6.48	IC50	328.9	nM	CHEMBL5424756
6.39	Kd	410	nM	CHEMBL4205347
6.36	IC50	440	nM	CHEMBL5430767
6.36	IC50	434.5	nM	CHEMBL5430767
6.21	IC50	609	nM	CHEMBL4217624
6.20	IC50	630	nM	CHEMBL5436656
6.20	IC50	626.6	nM	CHEMBL5436656
6.17	Kd	680	nM	CHEMBL4208692
6.16	IC50	700	nM	CHEMBL5420922
6.16	IC50	698.2	nM	CHEMBL5420922
6.10	IC50	800	nM	CHEMBL4279036
6.09	IC50	810	nM	CHEMBL5437088
6.09	IC50	811	nM	CHEMBL5437088
6.08	Kd	840	nM	CHEMBL4204363
6.05	IC50	890	nM	CHEMBL5427459
6.05	IC50	891.2	nM	CHEMBL5427459
5.95	IC50	1130	nM	CHEMBL5409821
5.95	IC50	1122	nM	CHEMBL5409821
5.93	Kd	1170	nM	CHEMBL4207015
5.88	Kd	1330	nM	CHEMBL4202667
5.88	Kd	1320	nM	CHEMBL4217624
5.88	IC50	1330	nM	CHEMBL5413708
5.88	IC50	1318	nM	CHEMBL5413708
5.86	Kd	1380	nM	CHEMBL4209931
5.85	Kd	1410	nM	CHEMBL4214846
5.84	Kd	1450	nM	CHEMBL4216033
5.84	Kd	1430	nM	CHEMBL4204935
5.82	Kd	1500	nM	CHEMBL4211378
5.81	Kd	1560	nM	CHEMBL4214327
5.81	IC50	1540	nM	CHEMBL5432970
5.81	IC50	1549	nM	CHEMBL5432970
5.80	IC50	1600	nM	CHEMBL4217624
5.75	Kd	1770	nM	CHEMBL4212550
5.73	Kd	1860	nM	CHEMBL4218751
5.73	Kd	1870	nM	CHEMBL4213216
5.70	IC50	2000	nM	CHEMBL387002
5.70	IC50	2000	nM	CHEMBL215821

PubChem BioAssay actives

118 with measured affinity, of 475 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-anilino-4-(4-methyl-2-morpholin-4-ylpyrimidin-5-yl)-1H-pyrimidin-6-one	2066984: Inhibition of [125I]-VEGF-A165 binding to NRP1 (unknown origin) in HUVEC cells	ic50	0.0006	uM
(4S)-4-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(3S,6S,9S,12S,15S,21S,24R,29R,32S,35S,38S,41S)-24-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-32-(4-aminobutyl)-3,35-dibenzyl-9-(3-carbamimidamidopropyl)-21-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-38-(1H-indol-3-ylmethyl)-12-(2-methylpropyl)-2,5,8,11,14,20,23,31,34,37,40-undecaoxo-26,27-dithia-1,4,7,10,13,19,22,30,33,36,39-undecazatricyclo[39.3.0.015,19]tetratetracontane-29-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-[[2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[(2S)-2-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.0134	uM
(4S)-4-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(3S,9S,12S,15S,21S,24R,29R,32S,35S,38S,41S)-24-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-9,21-bis(3-carbamimidamidopropyl)-3-(carboxymethyl)-35,38-bis(1H-indol-3-ylmethyl)-32-methyl-2,5,8,11,14,20,23,31,34,37,40-undecaoxo-12-propan-2-yl-26,27-dithia-1,4,7,10,13,19,22,30,33,36,39-undecazatricyclo[39.3.0.015,19]tetratetracontane-29-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-[[2-[[2-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[(2S)-2-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.0176	uM
(4S)-4-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(3S,6S,9S,12S,15S,21S,24R,29R,32S,35S,38S,41S)-24-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-benzyl-12-[(2S)-butan-2-yl]-9,32-bis(3-carbamimidamidopropyl)-21-(hydroxymethyl)-35,38-bis(1H-indol-3-ylmethyl)-6-(2-methylsulfanylethyl)-2,5,8,11,14,20,23,31,34,37,40-undecaoxo-26,27-dithia-1,4,7,10,13,19,22,30,33,36,39-undecazatricyclo[39.3.0.015,19]tetratetracontane-29-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-[[2-[[2-[[(2S)-6-amino-1-[[(2S)-1-[(2S)-2-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.0225	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.0390	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.0460	uM
(3S)-4-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-[[(1R,4S,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R,40S,43S,46S,49S,52S,55S,58R,65S,68R)-34,55-bis(4-aminobutyl)-13,52-bis(2-amino-2-oxoethyl)-25-(3-amino-3-oxopropyl)-7,28,40,65-tetrakis(3-carbamimidamidopropyl)-10,19-bis(2-carboxyethyl)-46-(carboxymethyl)-4,49-bis[(1R)-1-hydroxyethyl]-43-(hydroxymethyl)-58-[[(2S)-3-hydroxy-2-(octanoylamino)propanoyl]amino]-31-methyl-16,22-bis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,63,66-henicosaoxo-60,61,70,71-tetrathia-2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,64,67-henicosazabicyclo[35.25.10]doheptacontane-68-carbonyl]amino]-4-oxobutanoic acid	1369559: Binding affinity to recombinant human NRP1 extracellular domain by SPR method	kd	0.0760	uM
(4S)-4-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(3S,6S,9S,12S,15S,18S,21R,26R,29S,32S,35S,38S)-21-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-9,18,29-tris(3-carbamimidamidopropyl)-3-(hydroxymethyl)-6-(1H-imidazol-5-ylmethyl)-32,35-bis(1H-indol-3-ylmethyl)-15-methyl-12-(2-methylpropyl)-2,5,8,11,14,17,20,28,31,34,37-undecaoxo-23,24-dithia-1,4,7,10,13,16,19,27,30,33,36-undecazabicyclo[36.3.0]hentetracontane-26-carbonyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-[[2-[[2-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[(2S)-2-[(2S)-2-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.0763	uM
(4S)-4-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(3S,6S,9S,12S,15S,21S,24R,29R,32S,35S,38S,41S)-24-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-3,35-bis(4-aminobutyl)-32-benzyl-12-[(2S)-butan-2-yl]-9-(3-carbamimidamidopropyl)-6-(carboxymethyl)-38-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-2,5,8,11,14,20,23,31,34,37,40-undecaoxo-26,27-dithia-1,4,7,10,13,19,22,30,33,36,39-undecazatricyclo[39.3.0.015,19]tetratetracontane-29-carbonyl]amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-[[2-[[2-[[(2S)-6-amino-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-carbamimidamido-1-[(2S)-2-[(2S)-2-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.0967	uM
(4R)-4-[[2-[[(2R)-2-[[2-[[2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-4-carboxy-2-[[(2R)-2-[[2-[[2-[[(2R)-3-(4-hydroxyphenyl)-2-[[(2R)-2-[[2-[[(2R)-3-(4-hydroxyphenyl)-2-[[(2R)-2-[[(2R)-2-[(2-naphthalen-2-ylacetyl)amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]amino]butanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-5-[[(2R)-5-carbamimidamido-1-[(2R)-2-[(2R)-2-[[(1R)-4-carbamimidamido-1-carboxybutyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	2096070: Binding affinity to NRP1 (unknown origin) by MST analysis	kd	0.1056	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-6-(diaminomethylideneamino)-2-[[(2S)-2,3-diaminopropanoyl]amino]hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.3288	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-(pyridin-2-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	0.4100	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-[[(2S)-2,3-diaminopropanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.4345	uM
(2S)-2-[[3-[[5-[4-(aminomethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369537: Inhibition of biotinylated VEGF-A binding to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells after 2 hrs	ic50	0.6090	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-2-[[(2S)-2-amino-4-sulfanylbutanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.6266	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-(pyridin-2-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	0.6800	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-[[(2S)-2-amino-4-sulfanylbutanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.6982	uM
(2S)-2-[[(2S)-1-[4-amino-2-[[2-amino-6-(diaminomethylideneamino)hexanoyl]amino]butanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1421450: Inhibition of biotinylated VEGF165 binding to NRP1 (unknown origin) by ELISA	ic50	0.8000	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.8100	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-(1H-imidazol-2-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	0.8400	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-[[(2S)-2-amino-5-sulfanylpentanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	0.8900	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-(3-sulfanylpropanoylamino)hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	1.1220	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-(piperidin-1-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.1700	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-2-[[(2S)-2-amino-5-sulfanylpentanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	1.3183	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-[[4-(methylcarbamoyl)piperidin-1-yl]methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.3300	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-[(4-morpholin-4-ylpiperidin-1-yl)methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.3800	uM
(2S)-2-[[3-[[5-[3-[[4-(cyanomethyl)piperidin-1-yl]methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.4100	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-(1H-pyrazol-4-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.4300	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[3-(1H-pyrazol-5-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.4500	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-[(4-morpholin-4-ylpiperidin-1-yl)methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.5000	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	1.5400	uM
(2S)-2-[[3-[[5-[3-[(4-carbamoylpiperidin-1-yl)methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.5600	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-(1H-imidazol-2-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.7700	uM
(2S)-2-[[3-[[5-[2-[[4-(cyanomethyl)piperidin-1-yl]methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.8600	uM
(2S)-2-[[3-[[5-[2-(aminomethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	1.8700	uM
5-chloro-2-(3-fluorophenyl)-3-(2-phenylethylamino)indolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
5-chloro-2-phenyl-3-(2-phenylethylamino)indolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
5-chloro-2-(2-phenylethyl)-3-(2-phenylethylamino)indolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
5-chloro-3-(2-phenylethylamino)-2-pyridin-2-ylindolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
5-chloro-2-(3-methoxyphenyl)-3-(2-phenylethylamino)indolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
5-chloro-2-(4-chlorophenyl)-3-(2-phenylethylamino)indolizine-1-carbonitrile	269821: Inhibition of VEGF165-NRP1 interaction by ELISA	ic50	2.0000	uM
(2S)-2-[[3-[[5-[2-[(4-carbamoylpiperidin-1-yl)methyl]phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	2.0500	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-(1H-pyrazol-5-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	2.1000	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-(1H-pyrazol-4-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	2.1400	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-(2,3-dihydro-1H-isoindol-5-yl)-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	2.1700	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-6-(diaminomethylideneamino)-2-(3-sulfanylpropanoylamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	2.1700	uM
(2S)-2-[[(2S,3aS,7aS)-1-[(2S)-4-amino-2-[[(2S)-2-amino-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	1637868: Inhibition of human biotinylated VEGF-A165 binding to recombinant human NRP1 receptor after 2 hrs by chemiluminescence analysis	ic50	2.2387	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-amino-4-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]butanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	2.2387	uM
(2S)-5-(diaminomethylideneamino)-2-[[3-[[5-[2-(piperidin-1-ylmethyl)phenyl]-2,3-dihydro-1-benzofuran-7-yl]sulfonylamino]thiophene-2-carbonyl]amino]pentanoic acid	1369535: Binding affinity to N-terminal His6-tagged recombinant human NRP1-b1 domain expressed in Escherichia coli Rosetta Gami 2 (DE3) pLysS cells by SPR method	kd	2.2800	uM
(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-aminobutanoyl]amino]-6-[[(2S)-2-amino-6-(diaminomethylideneamino)hexanoyl]amino]hexanoyl]amino]butanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid	2016516: Inhibition of human biotinylated-VEGFA165 binding to recombinant human NRP-1 measured after 2 hrs by chemiluminescent based ELISA	ic50	2.3988	uM

CTD chemical–gene interactions

111 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression, affects expression	5
Valproic Acid	affects cotreatment, increases expression, decreases expression	5
bisphenol A	affects cotreatment, increases expression, affects expression, decreases expression, increases methylation	4
Benzo(a)pyrene	decreases expression, increases expression	4
(+)-JQ1 compound	affects cotreatment, decreases expression	3
Tetrachlorodibenzodioxin	affects expression, increases expression	3
Tretinoin	decreases expression, increases expression	3
Cyclosporine	decreases expression, increases expression, affects expression	3
sodium arsenate	decreases expression, increases abundance, increases expression	2
arsenite	increases expression, increases methylation, decreases reaction	2
cobaltous chloride	decreases expression	2
manganese chloride	decreases expression, increases abundance, increases expression, affects cotreatment	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Decitabine	affects cotreatment, decreases expression, decreases reaction	2
Troglitazone	increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression	2
Arsenic	increases expression, affects cotreatment, decreases expression, increases abundance	2
Cadmium	increases abundance, increases expression, decreases expression, decreases reaction	2
Copper	affects binding, increases expression	2
Doxorubicin	affects response to substance, decreases expression	2
Estradiol	decreases reaction, affects cotreatment, decreases expression, increases expression	2
Manganese	increases expression, affects cotreatment, decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Quercetin	affects expression, decreases expression	2
Tobacco Smoke Pollution	affects expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Aflatoxin B1	affects expression, increases expression	2

ChEMBL screening assays

50 unique, capped per target: 50 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1101244	Binding	Displacement of [125I]VEGF-A from human NRP1 expressed in pig aortic endothelial cells at 100 uM	Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. — J Med Chem

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1GN	Abcam A-549 NRP1 KO	Cancer cell line	Male
CVCL_D7W5	Ubigene A-549 NRP1 KO	Cancer cell line	Male
CVCL_TB09	HAP1 NRP1 (-) 1	Cancer cell line	Male
CVCL_UE43	293T human NRP1	Transformed cell line	Female
CVCL_XR14	HAP1 NRP1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE